Sensible Biotechnologies Analysis: $4M Raised
What is Sensible Biotechnologies?
Sensible Biotechnologies develops innovative mRNA manufacturing technologies for cost-efficient production of high-quality, non-immunogenic mRNA therapeutics and vaccines.
Employees
22
Founded
2021
Revenue
$1.3M
Business Model
Cell-based mRNA production platform; revenue from partnerships and funding rounds.
Product Features & Capabilities
- non-immunogenic mRNA, pure and highly functional mRNA, long mRNA for novel modalities, naturally modified mRNA for increased efficacy, cost-effective mRNA manufacturing, scalable mRNA production, cell-based platform for mRNA vaccines and therapeutics
How much Sensible Biotechnologies raised
Pre-Seed - $4.2 million
23 months agoLead Investor: Not specified in the sources.
Who are the founders of Sensible Biotechnologies
MG
Competitors Overview
Sensible Biotechnologies operates in the mRNA manufacturing market, focusing on a novel cell-based platform for producing high-quality mRNA therapeutics and vaccines. Its main competitors include:
- Moderna: Known for its mRNA COVID-19 vaccine, Moderna has a robust pipeline of mRNA-based thera
Investors
- Sensible Biotechnologies raised $4.2 million in a pre-seed financing round.
- The investors involved in this round include:
- The Venture Reality Fund
- The University of California, Berkeley
- The University of California, San Francisco
- Various angel investors
Market Focus
Sensible Biotechnologies primarily focuses on the biotechnology industry, specifically in the area of mRNA manufacturing for therapeutics and vaccines.
See something that needs updating? Suggest edits to this profile.